Insulin glargine-aglr

FDA Drug Profile — Rezvoglar KwikPen, REZVOGLAR KWIKPEN

Insulin glargine-aglr is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand names including Rezvoglar KwikPen, REZVOGLAR KWIKPEN. Available dosage form: injection, solution.

Drug details

Generic Name
Insulin glargine-aglr
Brand Names
Rezvoglar KwikPen, REZVOGLAR KWIKPEN
Application Number
BLA761215
Sponsor
Eli Lilly And Company
NDC Codes
2
Dosage Forms
INJECTION, SOLUTION
Routes
SUBCUTANEOUS
Active Ingredients
INSULIN GLARGINE

Indications and Usage

1 INDICATIONS AND USAGE REZVOGLAR™ is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. Limitations of Use REZVOGLAR is not recommended for the treatment of diabetic ketoacidosis. REZVOGLAR™ is a long-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 ) Limitations of Use : Not recommended for the treatment of diabetic ketoacidosis. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.